Your browser is no longer supported. Please, upgrade your browser.
ANIX [NASD]
Anixa Biosciences, Inc.
Index- P/E- EPS (ttm)-0.42 Insider Own3.90% Shs Outstand25.16M Perf Week-10.53%
Market Cap130.52M Forward P/E- EPS next Y-0.49 Insider Trans9.17% Shs Float23.35M Perf Month-5.56%
Income-9.60M PEG- EPS next Q-0.10 Inst Own5.80% Short Float2.27% Perf Quarter-19.81%
Sales0.50M P/S261.04 EPS this Y23.40% Inst Trans1.31% Short Ratio0.89 Perf Half Y110.40%
Book/sh0.54 P/B7.87 EPS next Y-19.50% ROA-97.90% Target Price- Perf Year134.81%
Cash/sh0.46 P/C9.32 EPS next 5Y- ROE-106.30% 52W Range1.70 - 8.09 Perf YTD38.44%
Dividend- P/FCF- EPS past 5Y-23.40% ROI- 52W High-46.60% Beta1.42
Dividend %- Quick Ratio9.50 Sales past 5Y- Gross Margin- 52W Low154.12% ATR0.33
Employees3 Current Ratio9.50 Sales Q/Q- Oper. Margin- RSI (14)43.63 Volatility7.64% 7.49%
OptionableYes Debt/Eq0.00 EPS Q/Q29.90% Profit Margin- Rel Volume0.26 Prev Close4.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume595.10K Price4.32
Recom2.00 SMA20-5.45% SMA50-12.27% SMA20024.73% Volume120,454 Change1.65%
Apr-12-21Initiated H.C. Wainwright Buy $11
May-07-21 08:30AM  
Apr-21-21 02:54PM  
Apr-19-21 12:58PM  
08:30AM  
Apr-14-21 09:13PM  
Apr-05-21 08:30AM  
Mar-22-21 10:00PM  
05:18PM  
08:30AM  
Mar-12-21 08:30AM  
Mar-08-21 08:30AM  
Mar-04-21 08:30AM  
Feb-25-21 08:30AM  
Feb-16-21 08:30AM  
Jan-13-21 08:30AM  
Jan-05-21 08:30AM  
Dec-21-20 08:30AM  
Dec-14-20 09:00AM  
Dec-11-20 08:45AM  
Dec-01-20 09:00AM  
Nov-23-20 08:30AM  
Oct-27-20 08:00AM  
Oct-25-20 08:30AM  
Sep-14-20 11:43AM  
Sep-08-20 08:00AM  
Aug-13-20 09:00AM  
Jul-28-20 09:00AM  
Jul-20-20 09:00AM  
Jul-10-20 07:25AM  
07:00AM  
Jul-06-20 09:00AM  
Jul-02-20 05:00PM  
Jun-01-20 08:30AM  
May-04-20 06:45AM  
Apr-28-20 06:32AM  
Apr-23-20 07:00AM  
Apr-21-20 06:00PM  
Apr-20-20 06:30AM  
Mar-23-20 06:28AM  
Mar-02-20 07:00AM  
Feb-12-20 07:00AM  
Feb-11-20 07:16AM  
Jan-06-20 07:00AM  
Jan-02-20 05:25AM  
Dec-23-19 07:00AM  
Dec-16-19 06:45AM  
Dec-13-19 05:45PM  
06:45AM  
Dec-02-19 07:00AM  
Nov-26-19 07:00AM  
Nov-22-19 07:00AM  
Nov-20-19 07:00AM  
Nov-07-19 07:00AM  
Nov-05-19 07:00AM  
Nov-03-19 07:38AM  
Oct-28-19 07:00AM  
Oct-25-19 07:00AM  
Oct-22-19 07:00AM  
Oct-15-19 07:00AM  
Oct-10-19 07:00AM  
Sep-23-19 07:00AM  
Sep-19-19 07:53AM  
07:00AM  
Sep-16-19 07:00AM  
Aug-26-19 07:00AM  
Jul-29-19 07:00AM  
Jul-24-19 07:00AM  
Jul-23-19 01:22PM  
Jul-22-19 07:00AM  
Jul-17-19 12:25PM  
07:00AM  
Jul-16-19 07:00AM  
May-29-19 07:00AM  
May-24-19 02:56PM  
May-21-19 07:00AM  
May-13-19 07:00AM  
May-02-19 07:00AM  
Apr-17-19 07:00AM  
Apr-11-19 07:00AM  
Apr-03-19 02:00PM  
Mar-27-19 07:00AM  
Mar-25-19 07:00AM  
Mar-14-19 07:00AM  
Mar-13-19 12:48PM  
Mar-04-19 07:00AM  
Feb-28-19 07:00AM  
Feb-25-19 07:00AM  
Feb-21-19 07:00AM  
Feb-13-19 07:00AM  
Feb-05-19 11:17AM  
Jan-25-19 07:00AM  
Jan-24-19 07:00AM  
Jan-16-19 07:30AM  
Dec-26-18 11:05AM  
Dec-19-18 07:00AM  
Dec-03-18 07:00AM  
Nov-15-18 07:00AM  
Nov-12-18 07:00AM  
Oct-29-18 07:00AM  
Oct-24-18 07:00AM  
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with OntoChem GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gottschalk EmilyDirectorApr 23Buy4.4910,00044,90025,600Apr 23 12:04 PM
Baskies Arnold MDirectorApr 20Buy3.9110,00039,10061,000Apr 20 01:27 PM
Titterton Lewis H jrDirectorApr 19Buy3.995,00019,950870,326Apr 20 10:32 AM
Gottschalk EmilyDirectorMar 25Buy4.8815,60076,12815,600Mar 26 09:41 AM
Titterton Lewis H jrDirectorMar 25Buy4.8445,000217,800865,326Mar 26 11:06 AM
KUMAR AMITChief Executive OfficerMar 25Buy4.865,00024,300277,000Mar 25 01:43 PM
KUMAR AMITChief Executive OfficerJan 29Buy3.7310,00037,300272,000Feb 01 09:00 AM
KUMAR AMITChief Executive OfficerSep 11Buy2.1128,00059,080262,000Sep 11 11:58 AM
Titterton Lewis H jrDirectorSep 11Buy2.0840,00083,2001,020,326Sep 14 09:29 AM
Titterton Lewis H jrDirectorJun 16Buy2.2724,50055,615980,326Jun 17 10:30 AM
Titterton Lewis H jrDirectorJun 15Buy2.2731,08370,558955,826Jun 16 11:43 AM
KUMAR AMITChief Executive OfficerJun 12Buy2.0320,00040,600234,000Jun 12 10:48 AM